Augment Health: Funding Rounds, Investors & CEO

About Augment Health

Augment Health, Inc. makes a noninvasive bladder monitor and an AI algorithm for patients with bladder dysfunction after a neurologic disease or injury. Patients wear a catheter attachment for 24 to 48 hours while it gathers bladder data. The data goes to a dashboard where clinicians review how a treatment is working and see whether it needs changes. The device is aimed at urology clinics. It is not yet for sale and has no FDA clearance.

Jared Meyers and Stephen Kalinsky founded the company in 2021. Both studied biomedical engineering at Georgia Tech. Meyers is co-founder and chief executive officer. Kalinsky is co-founder and chief technology officer. The company moved to Nashville in 2023 to join Vanderbilt University's Wond'ry Center of Innovation.

Funding Rounds (SEC Form D)

First sale	Filed with SEC	Amount sold	Investors	Avg. check	Terms	Filing
Oct 5, 2026	Oct 21, 2026amended Nov 5, 2026	$370,000of $800K target	3	$123K	EquityRule 506(b)	Form D/A ↗1 earlier filing
Jan 31, 2024	Feb 14, 2024amended Nov 13, 2025	$1,045,000of $2.0M target	10	$104K	Debt, Options, Securities on exerciseRule 506(b)	Form D/A ↗7 earlier filings
May 31, 2022	Jun 14, 2022amended Feb 9, 2023	$550,000of $1.3M target	9	$61,111	Options, Securities on exerciseRule 506(b)	Form D/A ↗5 earlier filings
Mar 10, 2022	Mar 24, 2022	$25,000fully sold	1	$25,000	OptionsRule 506(b)	Form D ↗
Not yet	Sep 17, 2021	$0of $75,000 target	2	$0	OptionsRule 506(b)	Form D ↗
Total, five offerings		$1,990,000

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Rounds announced by Augment Health

What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.

Announced	Round	Amount	Investors	Source
Feb 29, 2024	Funding round (investment from Vanderbilt University's Innovation Investment Committee)	Undisclosed	Vanderbilt University Innovation Investment Committee	Augment Health announces investment from Vanderbilt University as part of latest funding round ↗

Why Investors Backed Augment Health

Augment Health is building a bladder monitor to move testing for neurologic bladder dysfunction from the clinic to the home. It has finished a preclinical study and FDA pre-submission work. It is raising a $5.9M Series A to pay for a 10-patient clinical study, 510(k) clearance and a limited market release.

The problem it targets

Augment Health puts the number of patients with bladder dysfunction after a neurologic disease or injury at 7 million. Its case is that in-clinic tests fail often, with 44% coming back inconclusive. It also points to reversed bladder filling and rectal catheterization in current testing, which its data analysis is meant to remove. Its view is that traditional urodynamics bring scheduling delays and make symptoms hard to replicate.

What the product does

The monitor is meant to fit the current urology workflow. Revenue would come from a charge of about $210 per study, covering hardware and software. Augment Health's case is that clinics could bill $470 per study under codes they are newly eligible to use. By its estimate, one neuro-urology clinic would gain $282K a year in reimbursement. That clinic would be worth $126K a year in contract value to Augment Health. Sales would start with high-volume neuro-urology practices, then move to general urology practices with many chronic bladder patients.

Progress so far

Animal testing is done. Preclinical data show the sensor is more than 99% accurate in porcine bladders. The study was presented at the 2024 SUFU meeting. Final designs for production at scale are ready, and the product is in the final stages of transfer to manufacturing. FDA pre-submission meetings confirmed the 510(k) pathway for the Class II product. Regulatory testing, a 510(k) submission and a clinical study come next. The product carries U.S. Patent No. 12,491,333.

Who backs it

Vanderbilt University's Innovation Investment Committee invested in the company in February 2024. In all, $1.2M has been raised, with investments from Vanderbilt University, Georgia Tech and Regional One Health. An NIH grant application is pending. The medtech accelerators ZeroTo510 and MedTech Innovator support the company. Scientific advisors include Melissa Kaufman, chief of reconstructive urology and pelvic health at VUMC, and Emily Blum, a board-certified urologist. Chief executive officer Jared Meyers previously built stroke rehab devices at startups. Stephen Kalinsky built machine learning systems for research labs at Georgia Tech and Emory University.

We wrote this summary from public statements by Augment Health and its investors. It is not investment advice.

Augment Health in the News

Dec 1, 2022·Venture NashvilleVenture Notes - December 1, 2022
Sep 1, 2022·MobiHealthNewsQ&A: Developing an app to ease basic needs for people with neurological ...
Nov 17, 2021·Memphis Business Journal (Inno)Startup in Memphis innovates to make life easier for people with spinal cord ...

Leadership Team

Executive officers and directors listed on Augment Health's Form D filed Nov 5, 2026.

Jared Meyers

Co-Founder & CEO, director

LinkedIn ↗

Stephen Kalinsky

Co-Founder & CTO, director